ABVC BioPharma, Inc. cash flow to debt ratio of -85.99% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

ABVC BioPharma, Inc.'s free cash flow has decreased 65.07% from $-1.81M last year to $-2.99M, signaling decreasing performance

ABVC BioPharma, Inc.'s debt to equity ratio is 0.25, which means that the company's assets are healthy financed, signaling financial stability.

ABVC BioPharma, Inc.'s debt has decreased relative to shareholder equity from 2.61 last year to 0.25 today, signaling strengthened financials

ABVC BioPharma, Inc. has negative EBITDA, making leverage ratio unreliable

ABVC BioPharma, Inc.'s interest coverage ratio is -36.43, which means that the company struggles to meet interest obligations, signaling financial risk.

ABVC BioPharma, Inc.'s profit margin has increased (-223.04%) in the last year from -962.12% to 1.18K%, signaling increasing performance

ABVC BioPharma, Inc.'s short-term liabilities of $6.16M exceed its short-term assets of $2.50M, signaling financial risk

ABVC BioPharma, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

ABVC BioPharma, Inc.'s return on equity of -92.03%, is lower than 15.00%, indicating bad performance

ABVC BioPharma, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

ABVC BioPharma, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

ABVC BioPharma, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

ABVC BioPharma, Inc. has negative free cash flow, indicating cash burn

ABVC BioPharma, Inc.'s yearly earnings has decreased 61.30% since last year from $-4.90M to $-7.91M, signaling decreasing performance

ABVC BioPharma, Inc.'s yearly revenue has increased 56.19% since last year from $509.59K to $795.95K, signaling increasing performance

ROIC -56.73% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

ABVC BioPharma, Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

ABVC BioPharma, Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

ABVC BioPharma, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

ABVC BioPharma, Inc. has insufficient data to evaluate this check.

ABVC BioPharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

ABVC BioPharma, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

ABVC BioPharma, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

ABVC BioPharma, Inc. has insufficient data to evaluate this check.

ABVC BioPharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

ABVC BioPharma, Inc. has a price-to-book ratio of 1.88x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

ABVC BioPharma, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue